Amylin Pharmaceuticals (English Wikipedia)

Shannon Pettypiece (3 July 2012). "Bristol's Amylin Deal Heralds Acquisition Hunger". Bloomberg.com. Retrieved 21 February 2015.
Allison Connolly (19 December 2013). "AstraZeneca to Acquire Bristol Stake in Diabetes Venture". Bloomberg.com. Retrieved 21 February 2015.

daytondailynews.com

"Business as usual at Amylin plant during sale". daytondailynews. Retrieved 2017-05-25.

diabetesincontrol.com

"Dr. John Eng's Research Found That The Saliva Of The Gila Monster Contains A Hormone That Treats Diabetes Better Than Any Other Medicine". Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. 2007-09-18. Retrieved 2017-05-26.

diabetesjournals.org

care.diabetesjournals.org

Garber, Alan J. (2011-05-01). "Long-Acting Glucagon-Like Peptide 1 Receptor Agonists". Diabetes Care. 34 (Supplement 2): S279–S284. doi:10.2337/dc11-s231. ISSN 0149-5992. PMC 3632193. PMID 21525469.

doi.org

Garber, Alan J. (2011-05-01). "Long-Acting Glucagon-Like Peptide 1 Receptor Agonists". Diabetes Care. 34 (Supplement 2): S279–S284. doi:10.2337/dc11-s231. ISSN 0149-5992. PMC 3632193. PMID 21525469.

equilar.com

people.equilar.com

"Howard E. Greene Jr. - Executive Bio, Compensation History, and Contacts - Equilar Atlas". people.equilar.com. Archived from the original on 2016-08-13. Retrieved 2017-05-26.

fda.gov

U.S. Food and Drug Administration (25 February 2014). "FDA approves Myalept to treat rare metabolic disease". News & Events: Press Announcements. Retrieved 22 June 2015.

fdanews.com

"Diabetes Drug Byetta Gets FDA Approval". Retrieved 2017-05-26.

fool.com

"The Motley Fool, 3/20/98: The Daily Trouble". www.fool.com. Archived from the original on 2006-03-08. Retrieved 2017-05-26.

forbes.com

Moukheiber, Zina (2000-07-24). "Roller Coasting". Forbes. Retrieved 2017-05-26.

fundinguniverse.com

"History of Amylin Pharmaceuticals, Inc. – FundingUniverse". www.fundinguniverse.com. Retrieved 2017-05-26.

latimes.com

"Amylin's Offering a Success". Los Angeles Times. January 18, 1992. Retrieved June 3, 2024.
Gellene, Denise (September 21, 2002). "Eli Lilly to Join Forces With Amylin". Los Angeles Times. Retrieved June 3, 2024.
GELLENE, DENISE (2002-09-21). "Eli Lilly to Join Forces With Amylin". Los Angeles Times. ISSN 0458-3035. Retrieved 2017-05-26.

medpagetoday.com

"FDA Approves Symlin for Type 1 and Type 2 Diabetes". 2005-03-18. Retrieved 2017-05-26.

nih.gov

ncbi.nlm.nih.gov

Garber, Alan J. (2011-05-01). "Long-Acting Glucagon-Like Peptide 1 Receptor Agonists". Diabetes Care. 34 (Supplement 2): S279–S284. doi:10.2337/dc11-s231. ISSN 0149-5992. PMC 3632193. PMID 21525469.

pubmed.ncbi.nlm.nih.gov

Garber, Alan J. (2011-05-01). "Long-Acting Glucagon-Like Peptide 1 Receptor Agonists". Diabetes Care. 34 (Supplement 2): S279–S284. doi:10.2337/dc11-s231. ISSN 0149-5992. PMC 3632193. PMID 21525469.

nytimes.com

Chartrand, Sabra (1997-11-17). "Patents; Presenting amylin, which is being called the first new diabetes drug since the discovery of insulin". The New York Times. ISSN 0362-4331. Retrieved 2017-05-26.
Fisher, Lawrence M. (1995-06-22). "Amylin Gets Johnson Deal And Ends One With Glaxo". The New York Times. ISSN 0362-4331. Retrieved 2017-05-26.

dealbook.nytimes.com

Pollack, Michael J. de la Merced and Andrew (30 June 2012). "Bristol-Myers in Deal for Amylin Valued at $7 Billion". DealBook. Retrieved 2017-05-25.

sandiegouniontribune.com

Fikes, Bradley J. "Amylin's San Diego operations closing". sandiegouniontribune.com. Retrieved 2017-05-25.

sdbj.com

"Amylin Pharmaceuticals to Be Closed | San Diego Business Journal". www.sdbj.com. 3 April 2013. Retrieved 2017-05-25.

sec.gov

"Form 10-K". www.sec.gov. Retrieved 2017-05-26.

thepharmaletter.com

Letter, The Pharma. "Amylin to take Symlin back to clinic - Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2017-05-26.
Letter, The Pharma. "Amylin's Symlin US approval on hold - Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2017-05-26.

web.archive.org

"Howard E. Greene Jr. - Executive Bio, Compensation History, and Contacts - Equilar Atlas". people.equilar.com. Archived from the original on 2016-08-13. Retrieved 2017-05-26.
"The Motley Fool, 3/20/98: The Daily Trouble". www.fool.com. Archived from the original on 2006-03-08. Retrieved 2017-05-26.

worldcat.org

search.worldcat.org

Chartrand, Sabra (1997-11-17). "Patents; Presenting amylin, which is being called the first new diabetes drug since the discovery of insulin". The New York Times. ISSN 0362-4331. Retrieved 2017-05-26.
Fisher, Lawrence M. (1995-06-22). "Amylin Gets Johnson Deal And Ends One With Glaxo". The New York Times. ISSN 0362-4331. Retrieved 2017-05-26.
Garber, Alan J. (2011-05-01). "Long-Acting Glucagon-Like Peptide 1 Receptor Agonists". Diabetes Care. 34 (Supplement 2): S279–S284. doi:10.2337/dc11-s231. ISSN 0149-5992. PMC 3632193. PMID 21525469.
GELLENE, DENISE (2002-09-21). "Eli Lilly to Join Forces With Amylin". Los Angeles Times. ISSN 0458-3035. Retrieved 2017-05-26.

xconomy.com

"Amylin and Takeda Suspend Obesity Study to Consider Metreleptin Data | Xconomy". Xconomy. 2011-03-16. Retrieved 2017-05-25.
"Struggling Aegerion Diversifies With Fat Disease Drug | Xconomy". Xconomy. 2014-11-06. Retrieved 2017-05-25.

zenobank.com

"Company Profile for Amylin Pharmaceuticals Inc (AMLN)". Retrieved 2008-10-21.